The manufacturer of Spirocort® / Pulmicort ceases production permanently, and it is therefore expected that Spirocort® / Pulmicort pressurised inhalers, 100 µg/dose as well as 200 µg/dose, will be in short supply within a few months.
The manufacturer in Denmark has Spirocort® pressurised inhaler in stock, which is expected to cover demand until mid-April.
Spirocort® and Pulmicort are medicines used for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Spirocort® / Pulmicort turbuhaler and respules will still be available.
Doctors must find other treatment
Doctors must ensure that patients using Spirocort®/Pulmicort pressurised inhalers are given other treatment.
Other treatments proposed:
- For children who use Spirocort® / Pulmicort inhaler with a chamber, treatment with Flixotide® inhaler or Aerobec® inhaler, both with chambers, can be attempted. Dose adjustment is recommended.
- Older children can be treated with budesonide in other pharmaceutical forms.
Doctors should follow the dosage instructions of the concerned summaries of product characteristics and otherwise adjust the dose according to the patient’s condition and response to treatment. Please note that further information about glucocorticoids for inhalation is available in Danish at medicin.dk and in the Danish National Recommendation List (please follow the links in the right-hand factbox).
Please also see the announcement from the Institute for Rational Pharmacotherapy regarding Spirocort® / Pulmicort via the link in the factbox to the right (in Danish only).
We will post new information when the situation regarding Spirocort® / Pulmicort changes.
